Head of Product (AI-Powered Education Platform)
Noevo.io is an ambitious AI-first EdTech startup focused on revolutionizing student study abroad experiences. The Head of Product will own the product vision, strategy, and roadmap for their conversational AI advisor. This role requires leading cross-functional teams, driving user conversion, and collaborating with university partners. The position offers significant equity in an early-stage startup aiming for unicorn status.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
6-8 years
Function
Product Management
Work mode
Hybrid, United Kingdom
Company
Tier 2
What you will work on
Noevo.io is an ambitious AI-first EdTech startup focused on revolutionizing student study abroad experiences. The Head of Product will own the product vision, strategy, and roadmap for their conversational AI advisor. This role requires leading cross-functional teams, driving user conversion, and collaborating with university partners. The position offers significant equity in an early-stage startup aiming for unicorn status.
TAL's take
Solid early-stage leadership role with clear strategic responsibility in the AI-edtech space, though company brand is still emerging.
Clear leadership role with well-defined responsibilities, strategy, and team management expectations for an AI-first platform.
Must haves
- 6-8+ years of product management experience
- 2-3 years in a head of product or principal product role
- Track record shipping AI-powered consumer or education products
- Experience leading cross-functional teams
- Strong communication and stakeholder management skills
- Data-driven with analytical skills using mixpanel or amplitude
Tools and skills
Nice to have: conversational ai, recommendation systems.
About the company
Early-stage startup in the edtech domain, does not meet criteria for tier 1 global or India flagship status.
Posts mentioning Noevo.io
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market. - Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs. - Retail investors remain bullish on Amgen despite analyst disappointment. Source: [Asianet Newsable](https://newsable.asianetnews.com/markets/amgen-stock-sinks-on-modest-obesity-drug-results-but-retail-sentiment-remains-steady-snk9xh), [Asianet Newsable](https://newsable.asianetnews.com/markets/eli-lilly-novo-nordisk-shares-climb-premarket-as-biden-administration-mulls-medicare-medicaid-covering-for-obesity-drugs-retail-unmoved-snk72g)
The Controversial Rise of Weight Loss Drugs
- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)
The Looming Fiscal Crisis Over Revolutionary Weight Loss Drugs
- America faces a fiscal crisis over revolutionary weight loss drugs like Ozempic and Wegovy. - These drugs, produced by Novo Nordisk, have potential cardiovascular, mental health, and anti-cancer benefits. - However, their high cost in the U.S. compared to other countries could bankrupt Medicare. - If half of U.S. adults with obesity took these drugs, it would cost $411 billion annually. - The State Treasurer of North Carolina, Dale Folwell, is questioning the high cost and has asked the federal government to negotiate with Novo Nordisk to open up patents to generic manufacturers. Source: [More Perfect Union](https://youtu.be/JqHmvMjXuro)